AACR Annual Meeting 2017: Increasing the Number of Melanoma Patients Who Benefit From Immunotherapy
Identifying ways to increase the proportion of patients with melanoma who have clinically meaningful and durable responses to immune...
Identifying ways to increase the proportion of patients with melanoma who have clinically meaningful and durable responses to immune...
Guest Post by Roswell Park Cancer Institute Department of Public Affairs
Patients have long benefited from combination treatments—whether combining surgery with chemotherapy and radiation, or combining chemotherapy agents in succession.
As the spring weather encourages the planting of flowers, vegetables, and herbs, even careful gardeners may see weeds creeping...
Every month, the editors from the eight scientific journals published by the American Association for Cancer Research (AACR) select...
On Monday, the U.S. Food and Drug Administration (FDA) announced the highly anticipated approval of the molecularly targeted therapeutic...
Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard...
This post originally appeared on the Cancer Today website. Roads and roadblocks, both literal and metaphorical, figured into a...
August’s edition of Editors’ Picks includes biomarkers of immunotherapy response, individualized colorectal screening guidelines, and other exciting research.
While immunotherapy may be the latest tool in the treatment armamentarium for cancer, many ongoing clinical trials are assessing...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The...
Pancreatic cancer is notoriously challenging to treat, due largely to the fact that the disease is often diagnosed after...
Guest Post by Emer Smyth, PhD Assistant Director for the Stand Up To Cancer (SU2C) translational research grant programs, AACR
A plenary session at the AACR Annual Meeting 2024 explored how metastases adapt to—and help shape—their new environments.
On Tuesday, President Barack Obama signed H.R. 34, the 21st Century Cures Act (Cures), into law. The expansive bill...
When Abigail Johnston’s first child entered preschool six years ago, a vigilant pediatrician recommended an unusual strategy for minimizing...
Event cochair Dr. Michael Caligiuri shares how attendees can form connections to take science from bench to market.
Today, the American Association for Cancer Research (AACR) released its eighth annual Cancer Progress Report. The report highlights how...
AACR Project Genomics Evidence Neoplasia Information Exchange, or GENIE for short, has released one of the largest fully public...
In 1994, at the age of 40, Ginny Mason, RN, began noticing some concerning differences in the size and...
A special issue of Cancer Discovery illustrates the vast landscape of research being explored within the AACR community.
Dr. Patricia LoRusso works to find innovative therapeutics to reduce the toll of cancer on patients and their families.
Today’s early-career investigators are the future of cancer research and progress in the quest to prevent and cure cancer....
Three years ago, the American Association for Cancer Research (AACR) launched this blog with a welcome post from Chief...
May is National Cancer Research Month, during which the American Association for Cancer Research partners with advocacy groups, cancer...
If you or a loved one has ever been affected by cancer, the urge to aid and provide comfort...
The summer issue of Cancer Today is out and features stories on the challenge of having both cancer and...
The public craves solid health information, and knowledge about cancer research and treatment is vital to their well-being. The...
Editor’s note: February is Cancer Prevention Month. That’s why the American Association for Cancer Research (AACR) has been pleased...